You are here

  • Home
  • Archive
  • Volume 16, Issue 4
  • Cohort study finds newborn respiratory complications less common when mothers of babies with fetal lung immaturity at 34–37 weeks’ gestation given antenatal steroids

Article Text

Article menu
Download PDFPDF
Midwifery
Cohort study
Cohort study finds newborn respiratory complications less common when mothers of babies with fetal lung immaturity at 34–37 weeks’ gestation given antenatal steroids
  1. Beena D Kamath-Rayne1,
  2. Emily A DeFranco2,3
  1. 1Perinatal Institute and Division of Neonatology, Cincinnati Children's Hospital Medical Center
  2. 2Center for Prevention of Preterm Birth, Perinatal Institute, Cincinnati Children's Hospital Medical Center
  3. 3Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine
  1. Correspondence to : Dr Beena D Kamath-Rayne
    Perinatal Institute, Cincinnati Children's Hospital Medical Center, MLC 7009, 3333 Burnet Avenue, Cincinnati, OH 45229, USA; beena.kamath-rayne{at}cchmc.org
View Full Text

http://dx.doi.org/10.1136/eb-2012-101105

Statistics from Altmetric.com

    Commentary on: Yinon Y, Haas J, Mazaki-Tovi S, et al. Should patients with documented fetal lung immaturity after 34 weeks of gestation be treated with steroids? Am J Obstet Gynecol 2012;207:222.e1–4.OpenUrlCrossRefPubMed

    Implications for practice and research

    • Infants whose mothers were treated with antenatal corticosteroids (ANS) after documented fetal lung immaturity at >34 weeks’ gestation had a lower rate of composite respiratory morbidity.

    • There was no statistically significant difference in the rate of special care unit admission.

    • The study supports prolonging pregnancy as long as possible without incurring undue risk to the mother as the most beneficial approach to avoid prematurity-related newborn complications.

    Context

    Late preterm infants are the fast-growing proportion of preterm infants in the USA, and these infants are at risk for a variety of prematurity-related morbidities, …

    View Full Text

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions